A high-level working group will explore legal pathways to market for certain CBD products, according to the US FDA – which also revealed it had sent warning letters to three companies it accused of “unfounded claims”
Sign up to access our business and regulatory briefings and get the most updated news, insights and our expert analysis to keep you on top of worldwide industry trends.